NCT04698642View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

November 12, 2020

Study Completion Date

November 12, 2020

Conditions
Subcutaneous Fat
Interventions
DRUG

CBL-514

Both sides of the abdominal region will receive CBL-514.

Trial Locations (1)

Unknown

Investigational site, Melbourne

Sponsors
All Listed Sponsors
lead

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT04698642 - A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat | Biotech Hunter | Biotech Hunter